Trial Profile
AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Omacetaxine mepesuccinate (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms AML-02
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 19 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 25 Feb 2019 Status changed from recruiting to active, no longer recruiting.